These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22986230)

  • 1. Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer.
    Edmonds C; Hagan S; Gallagher-Colombo SM; Busch TM; Cengel KA
    Cancer Biol Ther; 2012 Dec; 13(14):1463-70. PubMed ID: 22986230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
    Sen M; Joyce S; Panahandeh M; Li C; Thomas SM; Maxwell J; Wang L; Gooding WE; Johnson DE; Grandis JR
    Clin Cancer Res; 2012 Sep; 18(18):4986-96. PubMed ID: 22825581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer.
    Li R; You S; Hu Z; Chen ZG; Sica GL; Khuri FR; Curran WJ; Shin DM; Deng X
    PLoS One; 2013; 8(9):e74670. PubMed ID: 24019973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.
    Boehm AL; Sen M; Seethala R; Gooding WE; Freilino M; Wong SM; Wang S; Johnson DE; Grandis JR
    Mol Pharmacol; 2008 Jun; 73(6):1632-42. PubMed ID: 18326051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells.
    Wu K; Chang Q; Lu Y; Qiu P; Chen B; Thakur C; Sun J; Li L; Kowluru A; Chen F
    Oncotarget; 2013 Dec; 4(12):2430-8. PubMed ID: 24280348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
    Chaib I; Karachaliou N; Pilotto S; Codony Servat J; Cai X; Li X; Drozdowskyj A; Servat CC; Yang J; Hu C; Cardona AF; Vivanco GL; Vergnenegre A; Sanchez JM; Provencio M; de Marinis F; Passaro A; Carcereny E; Reguart N; Campelo CG; Teixido C; Sperduti I; Rodriguez S; Lazzari C; Verlicchi A; de Aguirre I; Queralt C; Wei J; Estrada R; Puig de la Bellacasa R; Ramirez JL; Jacobson K; Ditzel HJ; Santarpia M; Viteri S; Molina MA; Zhou C; Cao P; Ma PC; Bivona TG; Rosell R
    J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28376152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma.
    Kato T; Jin CS; Lee D; Ujiie H; Fujino K; Hu HP; Wada H; Wu L; Chen J; Weersink RA; Kanno H; Hatanaka Y; Hatanaka KC; Kaga K; Matsui Y; Matsuno Y; De Perrot M; Wilson BC; Zheng G; Yasufuku K
    Int J Oncol; 2018 Nov; 53(5):2034-2046. PubMed ID: 30226590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
    Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
    Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
    Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erlotinib Pretreatment Improves Photodynamic Therapy of Non-Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms.
    Gallagher-Colombo SM; Miller J; Cengel KA; Putt ME; Vinogradov SA; Busch TM
    Cancer Res; 2015 Aug; 75(15):3118-26. PubMed ID: 26054596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment.
    Chu PL; Shihabuddeen WA; Low KP; Poon DJJ; Ramaswamy B; Liang ZG; Nei WL; Chua KLM; Thong PSP; Soo KC; Yeo ELL; Chua MLK
    Photodiagnosis Photodyn Ther; 2019 Sep; 27():367-374. PubMed ID: 31299389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity.
    Ung N; Putoczki TL; Stylli SS; Ng I; Mariadason JM; Chan TA; Zhu HJ; Luwor RB
    Cancer Biol Ther; 2014 May; 15(5):623-32. PubMed ID: 24556630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
    Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
    Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
    Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer.
    Zhang Q; Bhola NE; Lui VW; Siwak DR; Thomas SM; Gubish CT; Siegfried JM; Mills GB; Shin D; Grandis JR
    Mol Cancer Ther; 2007 Apr; 6(4):1414-24. PubMed ID: 17431120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.
    Song L; Rawal B; Nemeth JA; Haura EB
    Mol Cancer Ther; 2011 Mar; 10(3):481-94. PubMed ID: 21216930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained ERK [corrected] inhibition by EGFR targeting therapies is a predictive factor for synergistic cytotoxicity with PDT as neoadjuvant therapy.
    Weyergang A; Selbo PK; Berg K
    Biochim Biophys Acta; 2013 Mar; 1830(3):2659-70. PubMed ID: 23671927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer.
    Kluge A; Dabir S; Kern J; Nethery D; Halmos B; Ma P; Dowlati A
    Int J Cancer; 2009 Oct; 125(7):1728-34. PubMed ID: 19569236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.